“Atopic Dermatitis (AD) Pipeline Insight, 2020” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Atopic Dermatitis (AD) market.
A detailed picture of the Atopic Dermatitis (AD) pipeline landscape is provided, which includes the disease overview and Atopic Dermatitis (AD) treatment guidelines. The assessment part of the report embraces in-depth Atopic Dermatitis (AD) commercial assessment and clinical assessment of the Atopic Dermatitis (AD) pipeline products from the pre-clinical developmental phase to the marketed phase.
Atopic dermatitis (AD) is a condition frequently encountered in medical practices across the country. Treatments for AD need to rapidly control symptoms of the disease, improve quality of life and prevent exacerbations. The recognition of the genes responsible for defective barrier function is key to immune modulation and the development of newer classes of therapies, including Janus kinase signaling pathway inhibitors, additional PDE4 inhibitors, and agonists of the aryl hydrocarbon receptor.
Request for sample pages
Atopic dermatitis pipeline products
Expected launch of PF-04965842 (Pfizer), ZPL389 (Novartis Pharmaceuticals), DS-2741a (Daiichi Sankyo), Upadacitinib (AbbVie), PUR0110 (PurGenesis Technologies), Lebrikizumab (Dermira)and other shall fuel the growth of the market during the forecast period, i.e., 2020–2030.
Extensive research and development activities of pharmaceutical companies for developing the therapies for AD will significantly impact the market. Drugs in the clinical trials are expected to propel the growth of the AD drugs market in the upcoming years.
Key players such as Pfizer, Novartis Pharmaceuticals, Daiichi Sankyo, AbbVie, PurGenesis Technologies, Dermira and other are involved in developing therapies for Atopic Dermatitis.
In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Atopic Dermatitis (AD) collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.
Visit to know more
Report Highlights
Table of contents
1. Report Introduction
2. Atopic Dermatitis (AD)
3. Atopic Dermatitis (AD) Current Treatment Patterns
4. Atopic Dermatitis (AD) – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Atopic Dermatitis (AD) Late Stage Products (Phase-III)
7. Atopic Dermatitis (AD) Mid Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Atopic Dermatitis (AD) Discontinued Products
13. Atopic Dermatitis (AD) Product Profiles
14. Atopic Dermatitis (AD) Key Companies
15. Atopic Dermatitis (AD) Key Products
16. Dormant and Discontinued Products
17. Atopic Dermatitis (AD) Unmet Needs
18. Atopic Dermatitis (AD) Future Perspectives
19. Atopic Dermatitis (AD) Analyst Review
20. Appendix
21. Report Methodology
About DelveInsight
DelveInsight is a premier Business Consulting and Market Research firm, focused exclusively on the life science segment. With a wide array of smart end-to-end solutions, the firm helps the global Pharmaceutical and Bio-Tech companies formulate prudent business decisions for better growth in the market.
Browse through our vast repository from here.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Vinita Rakheja Email: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: AlbanyState: New YorkCountry: United StatesWebsite: www.delveinsight.com/